News & Events
PNOC019 open for patient enrollment, April 14th 2021
This international, multi-center clinical trial is open for patients (6 months – 22 years) with recurrent or progressive High Grade Glioma (HGG). The study aims to evaluate the immunological local and systemic changes following neoadjuvant checkpoint inhibition, as well as the preliminary efficacy of neoadjuvant checkpoint inhibition followed by surgery and adjuvant combination checkpoint inhibition in children and young adults with progressive or recurrent HGG.
PNOC007 open for patient enrollment, December 17th 2020
The purpose of this study is to test the safety and first signs of efficacy of a H3.3K27M specific peptide vaccine (K27M/TT), in combination with a drug called poly-ICLC and Nivolumab in children and young adults (3-21 years) that have been newly diagnosed with a diffuse intrinsic pontine glioma (DIPG) or another type of glioma. Thus is a multi-center clinical trial with multiple sites in the USA and one at the University Children’s Hospital Zurich in Switzerland.
SNF Sinergia Grant at DMG Center Zurich, November 26th 2020
The Swiss National Fund approved the Sinergia proposal of Dr. Javad Nazarian as the lead PI and Prof.Dr. Mehmet Fatih Yanik (ETH) and Dr.Sebastian Waszak (Centre for Molecular Medicine Norway) as co-applicants. With 3.1 Mio CHF over 4 years the team aims to merge novel technologies for rapid identification and validation of therapies capable of extending the survival of children diagnosed with diffuse midline gliomas. The proposal includes a stepwise process that employs expertise of a multidisciplinary team to achieve a significant impact on patient treatment options.
We are very much looking forward to first results from this interdisciplinary research team!
Trans-Atlantic DMG/DIPG Tumor board, November 9th 2020
The first Trans-Atlantic Tumor Board took place on November 9th, 2020 from 5 PM – 6 PM CET / 8 AM- 9 AM PT. More than 20 experts in the care of children and young adults with Diffuse Midline Glioma from UCSF and Zurich Children’s Hospital were present. The combined discussion with experts around the world truly enhances the evaluation and recommendations for these patients. The combined tumor board will take place on a weekly basis.